Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

NCT03409614 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

789

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: REGN2810
DRUG: REGN2810/chemo/ipi
OTHER: Chemotherapy
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]